Pivotal Legal Case Settlement Includes Ekso Bionics Ekso GT(TM) Robotic Exoskeleton

CANARY WHARF, LONDON, 2015-03-31 08:00 CEST (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, announced that Dale Messenger, who was left paralyzed with an L1 incomplete spinal cord injury after suffering a gunshot wound, settled a long running case at the High Court in the United Kingdom. His damages settlement includes, among other items, the purchase cost of an Ekso Bionics Ekso GT robotic exoskeleton, its replacement over the years, and related utilization costs.

"During my case, many subjects were discussed and items of equipment reviewed including other, similar exoskeletons. One such item was the Ekso and it proved to be more valuable than I could imagine, and in a league of its own," said Dale. "The benefit I experience from the Ekso ranges from pain relief, improvements to my bladder/bowel function and more recently an increase in my motor function and sensation."

Ben Rogers, Partner at Stewarts Law LLP, the UK's largest litigation only law firm that specializes in high value and complex disputes added: "So far as we are aware, this is the first time that damages have been recovered in England & Wales to reimburse for the cost of a home rehabilitation device and a trained physiotherapist to operate it. The settlement reflects both the ability in principle to recover damages for the Ekso Bionics robotic exoskeleton and of course the need for specialized medical and legal experts to assist with processing these claims."

Nathan Harding, Ekso Bionics chief executive officer adds, "This is a major step for individuals who are looking to improve their rehabilitation options from their home. We believe the data our partners are collecting at Europe's top rehabilitation centers will begin to show that the Ekso Bionics Ekso GT^TM robotic exoskeleton may be effective in many of the ways Dale has experienced, including aiding recovery and potentially reducing secondary complications. Now that we are seeing patients get access to our technology thru legal settlements for home rehabilitation, we are eager to see how this improved access might impact overall patient outcomes."

Ekso Bionics' lead product, the Ekso GT^TM robotic exoskeleton, is a wearable bionics suit that enables individuals with any amount of lower extremity weakness to stand up and walk over ground. Ekso Bionics is forging a new frontier in rehabilitation for people living with the consequences of stroke, spinal cord injury, and other neurological conditions affecting gait.

About Ekso Bionics (OTCQB:EKSO)

Since 2005, Ekso Bionics (http://www.eksobionics.com) has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available medical product called Ekso has helped thousands of people living with gait impairment or paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.

Facebook: www.facebook.com/eksobionics
Twitter: @eksobionics
YouTube: http://www.youtube.com/user/EksoBionics/

About Stewarts Law

The UK's largest litigation-only law firm specializes in high-value and complex disputes. Stewarts Law's lawyers are renowned for offering corporate clients and individuals innovative, ground-breaking solutions. Its specialist departments include aviation and travel, clinical negligence, commercial litigation, competition litigation, divorce and family, employment, international arbitration, investor protection litigation, personal injury and tax litigation. Each department has an international reputation for excellence. With international strategic partnerships in place with law firms around the world, Stewarts Law enables clients to take a global approach to litigation. Its Personal Injury department is consistently top-ranked by Chambers and Legal 500, the leading directories in the legal industry. 

Stewarts Law contact

Katy McEwen

Marketing Executive

Email: kmcewen@stewartslaw.com

Phone: (0)20 7822 8037

www.stewartslaw.com

Media Contact:

Heidi Darling, Director of Marketing Communications

Phone: 415.302.4777

hdarling@eksobionics.com

Investor Contact:

John Graziano, The Trout Group

Phone: 646.378.2942

jgraziano@troutgroup.com

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.